Whole Genome Sequencing of Matched Tumor, Adjacent Non-Tumor Tissues and Corresponding Normal Blood Samples of Hepatocellular Carcinoma Patients Revealed Dynamic Changes of the Mutations Profiles During Hepatocarcinogenesis.

Ruifang Mao,Jie Liu,Guanfeng Liu,Shanshan Jin,Qingzhong Xue,Liang Ma,Yan Fu,Na Zhao,Jinliang Xing,Lanjuan Li,Yunqing Qiu,Biaoyang Lin

DOI: https://doi.org/10.18632/oncotarget.15428

2017-01-01

Oncotarget

Abstract:Hepatocellular carcinoma (HCC) has become the third most deadly disease worldwide and HBV is the major factor in Asia and Africa. We conducted 9 WGS (whole genome sequencing) analyses for matched samples of tumor, adjacent non-tumor tissues and normal blood samples of HCC patients from three HBV positive patients. We then validated the mutations identified in a larger cohort of 177 HCC patients. We found that the number of the unique somatic mutations (average of 59,136) in tumor samples is significantly less than that in adjacent non-tumor tissues (average 83, 633). We discovered that the TP53 R249S mutation occurred in 7.7% of the HCC patients, and it was significantly associated with poor diagnosis. In addition, we found that the L104P mutation in the VCX gene (Variable charge, X-linked) was absent in white blood cell samples, but present at 11.1% frequency in the adjacent tissues and increased to 14.6% in HCC tissues, suggesting that this mutation might be a tumor driver gene driving HCC carcinogenesis. Finally, we identified a TK1-RNU7 fusion, which would result in a deletion of 103 amino acids from its C-terminal. The frequencies of this fusion event decreased from the adjacent tissues (29.2%) to the tumors (16.7%), suggesting that a truncated thymidine Kinase1 (TK1) caused by the fusion event might be deleterious and be selected against during tumor progression. The three-way comparisons allow the identification of potential driver mutations of carcinogenesis. Furthermore, our dataset provides the research community a valuable dataset for identifying dynamic changes of mutation profiles and driver mutations for HCC.